Lunaphore Technologies, a Lausanne, Switzerland-based medtech firm developing innovative next-generation devices for cancer tissue diagnostics, closed a CHF 5.3M Series B funding.
Together with the CHF 6M convertible loan received in October 2017, the overall financing round has reached CHF 11.3M.
Backers included Occident Group, Zürcher Kantonalbank, as well as investment funds from Asia, Switzerland and United Kingdom.
The company intends to use the funds to enable CE marking of its products and support product launch.
Founded in 2014 and led by CEO Ata Tuna Ciftlik, Lunaphore develops next generation tissue autostainers based on microfluidics technology which aims to perform assays much faster than standard techniques.
The company’s precision medicine solution – still in development and not for sale – performs ultra-rapid immunostainings and has already demonstrated good results in tests with cancer patient samples.